Objective： To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome, Methods： Eighty-fve patients [male 32, female 53; a...Objective： To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome, Methods： Eighty-fve patients [male 32, female 53; age （45.31±11,72） years] were given live combined Bifidobacterium, Lactobacillus and Enterococcus capsules 1260 mg/d t.i.d. ×4 weeks. Syndrome scales were used to evaluate the efficacy in gastrointestinal syndrome. Fecal flora was also measured before and after the treatment. Six bacteria were cultured and the colony forming units were counted in stool. SPSS was used for data analysis. Results： Seventy-four patients finished the follow-up. No side-effect was found. For treatment of irritable bowel syndrome, the effective rate of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules was 56.8% in the second week, 74.3% in the fourth week and 73.0% in the sixth week. Single symptom was improved, especially in abdominal pain and stool character. The probiotica containing live combined Bifidobacterium, Lactobacillus and Enterococcus could increase bifidobacterium count （P〈0.01） and lactobacillus count （P〈0.05）; decrease bacteroides count （P〈0.05） and enterococci count （P〈0.01）; No obvious changes were observed in clostridium diffcile colonitis and enterobacteriaceae （P〉0.05）. Conclusion： The result of the study indicated that the administration of live combined Bifidobacterium, Lactobacillus and Enterococcus improved the symptom of irritable bowel syndrome and that there was a gradual increase of this effect. Thereafter conditions remained stable for 2 weeks. That improvement may be associated with alterations in gastrointestinal flora.展开更多
Irritable bowel syndrome （IBS） is a common gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel movements. It affects 8%-22% of the population in Western co...Irritable bowel syndrome （IBS） is a common gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel movements. It affects 8%-22% of the population in Western countries and the prevalence of IBS prevalence is 5%-10% in most Asian communities^14 Akhough IBS is not a life-threatening disease,展开更多
文摘Objective： To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome, Methods： Eighty-fve patients [male 32, female 53; age （45.31±11,72） years] were given live combined Bifidobacterium, Lactobacillus and Enterococcus capsules 1260 mg/d t.i.d. ×4 weeks. Syndrome scales were used to evaluate the efficacy in gastrointestinal syndrome. Fecal flora was also measured before and after the treatment. Six bacteria were cultured and the colony forming units were counted in stool. SPSS was used for data analysis. Results： Seventy-four patients finished the follow-up. No side-effect was found. For treatment of irritable bowel syndrome, the effective rate of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules was 56.8% in the second week, 74.3% in the fourth week and 73.0% in the sixth week. Single symptom was improved, especially in abdominal pain and stool character. The probiotica containing live combined Bifidobacterium, Lactobacillus and Enterococcus could increase bifidobacterium count （P〈0.01） and lactobacillus count （P〈0.05）; decrease bacteroides count （P〈0.05） and enterococci count （P〈0.01）; No obvious changes were observed in clostridium diffcile colonitis and enterobacteriaceae （P〉0.05）. Conclusion： The result of the study indicated that the administration of live combined Bifidobacterium, Lactobacillus and Enterococcus improved the symptom of irritable bowel syndrome and that there was a gradual increase of this effect. Thereafter conditions remained stable for 2 weeks. That improvement may be associated with alterations in gastrointestinal flora.
文摘Irritable bowel syndrome （IBS） is a common gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel movements. It affects 8%-22% of the population in Western countries and the prevalence of IBS prevalence is 5%-10% in most Asian communities^14 Akhough IBS is not a life-threatening disease,
